Coherus Launches YUSIMRY(TM), a Biosimilar of Humira®, at $995 per Carton in U.S.

Stock Information for Coherus BioSciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Coherus BioSciences Inc.

Coherus to Participate in Upcoming Investor Conferences
Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025
Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise
Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes
Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting
Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update
Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025
Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.